Five-alpha-reductase Inhibitors for prostate cancer prevention

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Wilt, Timothy J ^a   MacDonald, R ^b   Hagerty, K ^b   Schellhammer, P ^b   Kramer, B S ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

AGE DISTRIBUTION; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COCHRANE LIBRARY; DIGITAL RECTAL EXAMINATION; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; EJACULATION DISORDER; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; FAMILY HISTORY; FATIGUE; FOLLOW UP; GLEASON SCORE; GROUPS BY AGE; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; MEDLINE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PREVALENCE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RACE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEXUAL DYSFUNCTION; SYMPTOM; UNSPECIFIED SIDE EFFECT;

EID: 44949142265     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007091     Document Type: Review

References (23)

1. ARIA/ARIB 2004 {published data only} Andriole GL, Roehrborn C, Schulman KM, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64:537-43.
2. *Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) inmen with benign prostatic hyperplasia.Urology 2002;60:434-41.
3. Cote 1998 {published data only} Cote RJ, Skinner EC, Salem CE, Mertes SJ, Stanczyk FZ, Henderson BE, et al.The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer 1998;78:413-8.
4. Foley 2000 {published data only} Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, et al.A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000;163:496-8.
5. FSG American 1992 {published data only} Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al.The effect of finasteride inmen with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;22:1185-91.
6. FSG Int. 1993 {published data only} Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-9.
7. Lee 2002 {published data only} Lee E. Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. J Int Med Res 2002;30:584-90.
8. MICTUS 2003 {published data only} Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2003;6:315-23.
9. MTOPS 2003 {published data only} McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al.The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
10. PCPT 2003 {published data only} Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al.The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
11. PLESS 1998 {published data only} Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al.Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998;52:195-02.
12. PREDICT 2003 {published data only} Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al.Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26.
13. PROSPECT 1996 {published data only} Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al.Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). Can Med Assoc J 1996;155:1251-9.
14. VA COOP 1996 {published data only} Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al.The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-9.
15. ACS 2007 American Cancer Society. Cancer Facts & Figures 2007. Atlanta: American Cancer Society, 2007.
16. Andriole 2004 Andriole G, Bostwick D, Brawley O, Gomella L,Marberger M, Tindall D, et al.Chemoprevention of prostate cancer inmen at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-7.
17. D'Amico 2006 D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol 2006;176:2010-2.
18. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
19. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
20. Lucia 2007 Lucia SM Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al.Finasteride and High-Grade Prostate Cancer in the PCPT. J Natl Cancer Inst 2007;99:1375-83.
21. Thompson 2006 Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al.Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33.
22. Thompson 2007 Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, et al.Finasteride improves the sensitivity of digital rectal examination for prostate cancer prevention. J Urol 2007;177:1749- 52.
23. Wilt 2008 Wilt TJ, Shamliyan T, Taylor B, MacDonald R, Tacklind J, Rutks I, et al.Comparison of Therapies for Clinically Localized Prostate Cancer. Evidence Report/Technology Assessment No. xxx (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-02-0009.). AHRQ Publication No. xx-xxxx. Rockville, MD: Agency for Healthcare Research and Quality, 2008 (in press).